Regenlab USA (RGNA) investor relations material

Company overview and business model

• Science-driven regenerative medicine company with vertically integrated operations across the US, Switzerland, and France, focusing on autologous biologics and tissue engineering platforms.

• Product portfolio spans musculoskeletal regeneration, advanced wound care, medical aesthetics, and women's health, with over 70 patents and 300 clinical studies supporting efficacy.

• Commercialization through direct sales in key markets and global distribution partnerships; recent strategic alliances include MiMedx, OPKO Health, Smith+Nephew, and Stryker.

• Lead products include PRP kits, PRP+HA combination devices, and wound care gels, with regulatory clearances in the US (FDA 510(k)), EU (CE-MDR), and other regions.

• Recent corporate restructuring established a US-based holding company, with the founder retaining majority control.

Financial performance and metrics

• FY2025 revenue: $49.17M (+1.6% YoY); gross profit: $34.24M (69.6% margin); net loss: $(1.24)M (vs. $2.31M net income in FY2024).

• H1 2026 revenue: $29.32M (+21% YoY); net income: $71K (vs. $(32)K in H1 2025); operating cash flow: $5.0M.

• Working capital deficit as of June 30, 2026: $12.8M; cash and equivalents: $4.8M; total indebtedness: $22.16M.

• R&D expenses increased to $6.49M in 2025 (13% of revenue), supporting multiple clinical and regulatory programs.

• Main revenue drivers: RegenKit PRP (62% of FY2025 revenue) and Cellular Matrix (28.6%).

Use of proceeds and capital allocation

• Net proceeds from IPO to be allocated: ~60% to sales and marketing, 10% to equipment for factories, 30% to R&D and regulatory expenses, and the remainder to working capital and general corporate purposes.

• Proceeds expected to fund operations for at least 12 months; additional capital may be required if growth or regulatory milestones accelerate.